Can larotinib/larlotinib be taken blindly?

Larotrectinib is a specific anti-tumor drug targeting NTRK gene fusion mutations. It is widely used to treat a variety of adult and pediatric malignant tumors, such as infantile sarcoma and cystic mature teratoma. It inhibits tumor growth by precisely attacking the protein kinase produced by NTRK gene fusion.

In multiple clinical trials, larotrectinib has demonstrated excellent therapeutic effects. Especially for those patients who are confirmed by genetic testing to carry NTRK gene fusion mutations, the efficacy of this drug is particularly significant. Data show that in these specific patient groups, the overall response rate and survival rate of larotrectinib treatment are at a high level, and the treatment success rate for patients with solid tumors carrying this mutation can reach approximately 75%.

However, a noteworthy issue is that the efficacy of larotrectinib is highly dependent on whether the patient actually carriesNTRK gene fusion mutation. For those patients who do not have this specific genetic mutation, use of larotrectinib may not result in the expected therapeutic benefit. That's why before starting treatment, doctors often recommend genetic testing to ensure the drug is working as effectively as possible.

Of course, like all drugs, larotrectinib may also be associated with some side effects, such as fatigue, nausea, vomiting, and diarrhea. Therefore, when prescribing, doctors will carefully consider the patient's specific condition and continue to monitor the patient's response during treatment to ensure the safety and effectiveness of the treatment.

For those patients who "blindly take" larotrectinib without genetic testingthe efficacy is highly uncertain. While some patients may benefit from treatment because they happen to carry an NTRK gene fusion mutation, many more patients who do not carry the mutation may not benefit from treatment. Therefore, to ensure treatment efficacy and patient safety, it is crucial to perform genetic testing to guide treatment selection.